Literature DB >> 25712010

The asthma COPD overlap syndrome (ACOS).

Stephen Bujarski1, Amit D Parulekar, Amir Sharafkhaneh, Nicola A Hanania.   

Abstract

Asthma and chronic obstructive pulmonary disease (COPD) have traditionally been viewed as distinct clinical entities. Recently, however, much attention has been focused on patients with overlapping features of both asthma and COPD: those with asthma COPD overlap syndrome (ACOS). Although no universal definition criteria exist, recent publications attempted to define patients with ACOS based on differences in clinical features, radiographic findings, and diagnostic tests. Patients with ACOS make up a large percentage of those with obstructive lung disease and have a higher overall health-care burden. Identifying patients with ACOS has significant therapeutic implications particularly with the need for early use of inhaled corticosteroids and the avoidance of use of long-acting bronchodilators alone in such patients. However, unlike asthma and COPD, no evidence-based guidelines for the management of ACOS currently exist. Future research is needed to improve our understanding of ACOS and to achieve the best management strategies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25712010     DOI: 10.1007/s11882-014-0509-6

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  75 in total

1.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.

Authors:  P S Burge; P M Calverley; P W Jones; S Spencer; J A Anderson; T K Maslen
Journal:  BMJ       Date:  2000-05-13

Review 2.  Clinical phenotypes of COPD: identification, definition and implications for guidelines.

Authors:  Marc Miravitlles; Myriam Calle; Juan José Soler-Cataluña
Journal:  Arch Bronconeumol       Date:  2011-12-22       Impact factor: 4.872

3.  Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment.

Authors:  R Leigh; M M M Pizzichini; M M Morris; F Maltais; F E Hargreave; E Pizzichini
Journal:  Eur Respir J       Date:  2006-01-30       Impact factor: 16.671

4.  Effects of tiotropium on lung function in severe asthmatics with or without emphysematous changes.

Authors:  Makoto Yoshida; Takako Nakano; Satoru Fukuyama; Takafumi Matsumoto; Miyuki Eguchi; Atsushi Moriwaki; Shohei Takata; Kentaro Machida; Akiko Kanaya; Koichiro Matsumoto; Yoichi Nakanishi; Hiromasa Inoue
Journal:  Pulm Pharmacol Ther       Date:  2012-10-13       Impact factor: 3.410

5.  Characteristics of COPD phenotypes classified according to the findings of HRCT.

Authors:  Yoshiaki Kitaguchi; Keisaku Fujimoto; Keishi Kubo; Takayuki Honda
Journal:  Respir Med       Date:  2006-03-23       Impact factor: 3.415

Review 6.  Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis.

Authors:  Sonal Singh; Aman V Amin; Yoon K Loke
Journal:  Arch Intern Med       Date:  2009-02-09

7.  Predictors of response to tiotropium versus salmeterol in asthmatic adults.

Authors:  Stephen P Peters; Eugene R Bleecker; Susan J Kunselman; Nikolina Icitovic; Wendy C Moore; Rodolfo Pascual; Bill T Ameredes; Homer A Boushey; William J Calhoun; Mario Castro; Reuben M Cherniack; Timothy Craig; Loren C Denlinger; Linda L Engle; Emily A Dimango; Elliot Israel; Monica Kraft; Stephen C Lazarus; Robert F Lemanske; Njira Lugogo; Richard J Martin; Deborah A Meyers; Joe Ramsdell; Christine A Sorkness; E Rand Sutherland; Stephen I Wasserman; Michael J Walter; Michael E Wechsler; Vernon M Chinchilli; Stanley J Szefler
Journal:  J Allergy Clin Immunol       Date:  2013-09-29       Impact factor: 10.793

8.  Bronchodilator responsiveness in patients with COPD.

Authors:  D P Tashkin; B Celli; M Decramer; D Liu; D Burkhart; C Cassino; S Kesten
Journal:  Eur Respir J       Date:  2008-02-06       Impact factor: 16.671

9.  Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD.

Authors:  Nicola A Hanania; Peter M A Calverley; Mark T Dransfield; Jill P Karpel; Manja Brose; Haiyuan Zhu; Udo-Michael Goehring; Paul Rowe
Journal:  Respir Med       Date:  2013-09-30       Impact factor: 3.415

10.  A new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC).

Authors:  Marc Miravitlles; Juan José Soler-Cataluña; Myriam Calle; Jesús Molina; Pere Almagro; José Antonio Quintano; Juan Antonio Trigueros; Pascual Piñera; Adolfo Simón; Juan Antonio Riesco; Julio Ancochea; Joan B Soriano
Journal:  Prim Care Respir J       Date:  2013-03
View more
  23 in total

1.  Current situation of asthma-COPD overlap syndrome (ACOS) in Chinese patients older than 40 years with airflow limitation: rationale and design for a multicenter, cross-sectional trial (study protocol).

Authors:  Jian Kang; Wanzhen Yao; Baiqiang Cai; Ping Chen; Xia Ling; Hongyan Shang
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

Review 2.  The Reemergence of the Asthma-COPD Overlap Syndrome: Characterizing a Syndrome in the Precision Medicine Era.

Authors:  Stephanie A Christenson
Journal:  Curr Allergy Asthma Rep       Date:  2016-11       Impact factor: 4.806

Review 3.  Chronic obstructive pulmonary disease classification, phenotypes and risk assessment.

Authors:  Prasad Manian
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

Review 4.  Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management.

Authors:  Prescott G Woodruff; Alvar Agusti; Nicolas Roche; Dave Singh; Fernando J Martinez
Journal:  Lancet       Date:  2015-05-02       Impact factor: 79.321

5.  Eosinophils in COPD: why should I care?

Authors:  Frederico Leon Arrabal Fernandes
Journal:  J Bras Pneumol       Date:  2016 Jul-Aug       Impact factor: 2.624

6.  Tests for confounding with cigarette smoking in the association of E-cigarette use with respiratory disorder: 2020 National-Sample Data.

Authors:  Thomas A Wills; Kelvin Choi; Pallav Pokhrel; Ian Pagano
Journal:  Prev Med       Date:  2022-07-09       Impact factor: 4.637

7.  Histopathological Type of Lung Cancer and Underlying Driver Mutations in Patients with Chronic Obstructive Pulmonary Disease (COPD) versus Patients with Asthma and COPD Overlap: A Single-Center Retrospective Study.

Authors:  Tamami Sakai; Johsuke Hara; Kenta Yamamura; Miki Abo; Akihito Okazaki; Noriyuki Ohkura; Kazuo Kasahara
Journal:  Turk Thorac J       Date:  2020-03-01

Review 8.  Extracellular Vesicles as Central Mediators of COPD Pathophysiology.

Authors:  Derek W Russell; Kristopher R Genschmer; J Edwin Blalock
Journal:  Annu Rev Physiol       Date:  2021-11-01       Impact factor: 19.318

9.  Glucocorticoids and antibiotics, how do they get together?

Authors:  Joachim Reidl; Eduard Monsó
Journal:  EMBO Mol Med       Date:  2015-08       Impact factor: 12.137

Review 10.  Benralizumab: a unique IL-5 inhibitor for severe asthma.

Authors:  Laren D Tan; Jennifer M Bratt; Dorottya Godor; Samuel Louie; Nicholas J Kenyon
Journal:  J Asthma Allergy       Date:  2016-04-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.